A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Carcinoma, Non-small-cell Lung

In brief

The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to patients with stage IIIB and IV non-small cell lung cancer. This study will also evaluate the preliminary efficacy (Phase II component) of bexarotene oral capsules in combination with the weekly Taxol® schedule and carboplatin in these patients.

Key facts

Study ID

NCT00153842

Run by

Dartmouth-Hitchcock Medical Center

People needed

33

Starts

2001-08-01

Expected to finish

2009-03-01

Last updated by the study team

2019-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• unresectable stage IIIB or IV NSCLC
• adequate bone marrow, hepatic, thyroid and renal function

You may not qualify if…

• peripheral neuropathy >= grade 2
• gastrointestinal abnormalities
• known hypersensitivity to retinoids

Where it is running

• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.